 BOSTON, Sept. 01, 2022 GLOBE NEWSWIRE -- Albireo Pharma, Inc. Nasdaq: ALBO, a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in upcoming investor conferences: 